← Eichor
Condition: Pd 1 Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Pd 1

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic On
Phase 2 · 2 location(s) · Fudan University · NCT05281003BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Phase 2 · 33 location(s) · SCRI Development Innovations, LLC · NCT06773910The Immune Assessment of PD-1 Antibody Therapy in Tumor
Phase N/A · 1 location(s) · Quanli Gao · NCT06693440To Evaluate the Efficacy and Safety of Inhaled Corticosteroids Combined With Bronchodilators and Programmed Death-ligand
Phase N/A · 1 location(s) · Guangzhou Institute of Respiratory Disease · NCT06772454A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Phase 1/Phase 2 · 103 location(s) · AstraZeneca · NCT06996782A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Benefi
Phase 1/Phase 2 · 68 location(s) · BioNTech SE · NCT07111520TCR-T Cell Therapy on Advanced Solid Tumors
EARLY_Phase 1 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT05438667A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-0
Phase 2 · 38 location(s) · Merck Sharp & Dohme LLC · NCT06961006Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
Phase 4 · 4 location(s) · Icahn School of Medicine at Mount Sinai · NCT03781752This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P
Phase 1 · 1 location(s) · Beam Therapeutics Inc. · NCT07304791A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Phase 2 · 83 location(s) · AstraZeneca · NCT07098338Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First
Phase 1/Phase 2 · 51 location(s) · Merck Sharp & Dohme LLC · NCT06469944A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chem
Phase 2 · 24 location(s) · BioNTech SE · NCT07255404Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Ca
Phase 2 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT07281768A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 3 · 1 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT06629597A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Meta
Phase 2 · 25 location(s) · Regeneron Pharmaceuticals · NCT06769698Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523529Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patient
Phase 2 · 1 location(s) · Qian Chu · NCT06001151Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients
Phase 1 · 1 location(s) · Innopeutics Corporation · NCT07371338Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for R
Phase 2 · 8 location(s) · Gruppo Oncologico del Nord-Ovest · NCT06869473Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a
Phase 1/Phase 2 · 6 location(s) · Phanes Therapeutics · NCT05431270A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advance
Phase 3 · 312 location(s) · AstraZeneca · NCT06692738Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During o
Phase 1/Phase 2 · 30 location(s) · Merck Sharp & Dohme LLC · NCT07049926A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults.
Phase 1 · 1 location(s) · Changchun GeneScience Pharmaceutical Co., Ltd. · NCT07366866Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Phase 1/Phase 2 · 6 location(s) · Simcha IL-18, Inc. · NCT04787042KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used W
Phase 1/Phase 2 · 46 location(s) · Merck Sharp & Dohme LLC · NCT04165070Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
Phase 1/Phase 2 · 3 location(s) · Ashvattha Therapeutics, Inc. · NCT05395624Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
Phase 1/Phase 2 · 17 location(s) · Nykode Therapeutics ASA · NCT06016920A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Met
Phase 1/Phase 2 · 11 location(s) · Iovance Biotherapeutics, Inc. · NCT05361174
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.